trial

Trial of Stimulus-response Potentiation in Schizophrenia

NCTId NCT03892876
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 120 (actual)
Sponsored by Cairo University
Primary completion 2021-04-15
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
120 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2019-09-01
Primary completion
2021-04-15
Eligibility
MALE · 20 Years · 50 Years

Interventions & indications

Drugs
Auditory High Frequency Tetanizing Stimulation

Sponsors

Cairo UniversityLead Sponsor
University of Pittsburgh Medical CenterCollaborator

Investigators

2
Ola O Shahin, MDStudy Director
Vishwajit Laxmikant Nimgaonkar, MD PhDStudy Director

Sites

1 total
Cairo, Egypt

Facts & assertions

4 sourced
Enrollment
120
Phase
NA
Primary Completion Date
2021-04-15
Status
COMPLETED
relationships
The graph out of here
drug
Auditory High Frequency Tetanizing Stimulation
drug
lead_sponsor
Cairo University
company
collaborator
University of Pittsburgh Medical Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Ola O Shahin, MD
person
Vishwajit Laxmikant Nimgaonkar, MD PhD
person